semaglutide mash approval CDSCO Clears Wegovy for — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on semaglutide approved for mash Semaglutide's

8 Challenges and Considerations in Multi-Agonist Therapy Despite their advantages, GLP-1-based therapies face several challenges in adolescent populations: Gastrointestinal Side Effects: Nausea, vomiting, diarrhea, and constipation are common adverse events, especially during dose escalation

However, it can help manage symptoms like weight gain and insulin resistance, making the condition easier to live with

These medications are not recommended for patients with a personal or family history of medullary thyroid carcinoma or MEN 2

The CFC [Catalyst for a Cure] funding made it possible for me to transition half my laboratory into the study of glaucoma and neural repair and ganglion cell repair and regeneration

.F.-M.: Conceptualization, Formal analysis, Investigation, Methodology, Validation, Supervision, Writingoriginal draft, Writingreview and editing